CoChat

Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants

Open access
Chen, Tao, Cheng, Ling, Ma, Jingwen, Yuan, Jiyuan, Pi, Chao, Xiong, Linjin, Chen, Jinglin, Liu, Huiyang, Tang, Jia, Zhong, Yueting, Zhang, Xiaomei, Liu, Zerong, Zuo, Ying, Shen, Hongping, Wei, Yumeng, Zhao, Ling · 2023 · Pharmacological Research
Cited by 52

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Major depressive disorder (MDD) is a chronic relapsing psychiatric disorder. Conventional antidepressants usually require several weeks of continuous administration to exert clinically significant therapeutic effects, while about two-thirds of the patients are prone to relapse of symptoms or are completely ineffective in antidepressant treatment. The recent success of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine as a rapid-acting antidepressant has propelled extensive research on the action mechanism of antidepressants, especially in relation to its role in synaptic targets. Studies have revealed that the mechanism of antidepressant action of ketamine is not limited to antagonism of postsynaptic NMDA receptors or GABA interneurons. Ketamine produces powerful and rapid antidepressant effects by affecting α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors, adenosine A1 receptors, and the L-type calcium channels, among others in the synapse. More interestingly, the 5-HT2A receptor agonist psilocybin has demonstrated potential for rapid antidepressant effects in depressed mouse models and clinical studies. This article focuses on a review of new pharmacological target studies of emerging rapid-acting antidepressant drugs such as ketamine and hallucinogens (e.g., psilocybin) and briefly discusses the possible strategies for new targets of antidepressants, with a view to shed light on the direction of future antidepressant research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2023.106837

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 52

Metadata

Authors
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., Zhang, X., Liu, Z., Zuo, Y., Shen, H., Wei, Y., & Zhao, L.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2023-08
Volume
194
Pages
106837
ISSN
1043-6618 (ISSN-L)
OpenAlex
W4382133350
Cited by
52
References
67
FWCI
6.66
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. https://app.cochat.ai/papers/10.1016/j.phrs.2023.106837
The paper
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., Zhang, X., Liu, Z., Zuo, Y., Shen, H., Wei, Y., & Zhao, L. (2023). Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. Pharmacological Research. https://doi.org/10.1016/j.phrs.2023.106837

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.